Eliquis Shows Lower Incidence of Adverse Events Including Major Bleeding in PIII Study in Patients with Acute VTE

Bristol-Myers K.K. and Pfizer Japan announced on April 27 that the novel oral anticoagulant Eliquis Tablets 2.5 mg and 5 mg (apixaban), a direct factor Xa inhibitor, was associated with a lower incidence of adverse events including major bleeding than...read more